Development and validation of an MBD3/UHRF1 methylation-regulator-based prognostic model for pancreatic cancer survival
Translational Cancer Research · 2025-06 · 14 (6) · 3542-3553
DOI: 10.21037/tcr-24-1887 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Cancer Research, 2025-06. Verfasst von Xue Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
DNA methylation plays a crucial role in the onset and progression of cancer. However, the complex technology and high costs required for methylation detection limit its clinical application. DNA methylation regulators are essential for maintaining the precision and stability of gene methylation, and their aberrant expression can lead to abnormal methylation levels. Whereas the role of combinatorial methylation regulators in pancreatic cancer (PCA) risk remains unclear, we developed a model using 20 DNA methylation regulators to predict patient prognosis and assess treatment response.
Methods
Gene expression and clinical data from 331 PCA patients [The Cancer Genome Atlas (TCGA)-PCA, n=177; Gene Expression Omnibus (GEO)-PCA, n=154] were analyzed. TCGA data were used as the training set, and GEO data were used as the validation set. Inclusion criteria were complete survival data. Univariate and least absolute shrinkage and selection operator (LASSO)-Cox regression identified prognostic DNA methylation regulators. The model's predictive accuracy was validated using time-dependent receiver operating characteristic (ROC) curves. Differences in immune cell infiltration and drug sensitivity were also assessed.
Results
A total of 331 PCA patients were analyzed, with a median overall survival (OS) of 1.2 and 1.4 years, respectively. Univariate Cox regression identified seven DNA methylation regulators (DNMT3A, TET3, MBD3, MBD2, ZBTB38, UHRF1, UNG) associated with prognosis, of which MBD3 and UHRF1 were selected via LASSO-Cox regression to construct the final model. The model demonstrated robust prognostic performance, with low-risk patients in both cohorts showing significantly longer OS compared to high-risk groups (P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Oncology, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
- Department of Rehabilitation Medicine, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Xue Cheng
Zitieren
APA
Cheng, X., Zhang, Y., Wang, C., & Chen, K. (2025). Development and validation of an MBD3/UHRF1 methylation-regulator-based prognostic model for pancreatic cancer survival. Translational Cancer Research, 14(6), 3542-3553. https://doi.org/10.21037/tcr-24-1887
Vancouver
Cheng X, Zhang Y, Wang C, Chen K. Development and validation of an MBD3/UHRF1 methylation-regulator-based prognostic model for pancreatic cancer survival. Translational Cancer Research. 2025;14(6):3542-3553. doi:10.21037/tcr-24-1887
BibTeX
@article{Cheng2025,
author = {Cheng, Xue and Zhang, Yangmei and Wang, Chunbin and Chen, Kai},
title = {Development and validation of an MBD3/UHRF1 methylation-regulator-based prognostic model for pancreatic cancer survival},
journal = {Translational Cancer Research},
year = {2025},
volume = {14},
number = {6},
pages = {3542--3553},
doi = {10.21037/tcr-24-1887}
}
EUVIMED